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Objectives The aim of this study was to analyze the CAPTURE 2 (Carotid ACCULINK/ACCUNET Post
Approval Trial to Uncover Rare Events) study for physician- or site-related variables associated with
differential outcomes for carotid artery stenting (CAS).
Background The CAPTURE 2 trial is an ongoing, prospective, nonrandomized, independently adjudi-
cated, multicenter clinical study enrolling high-surgical-risk patients undergoing CAS.
Methods In this assessment of the CAPTURE 2 study, the American Heart Association carotid endar-
terectomy guideline limits were used to deﬁne acceptable site and physician CAS outcomes; there-
fore, the resulting population of nonoctogenarian, asymptomatic subjects in this analysis is conﬁned
to 3,388 (of the total 5,297) subjects treated at 180 U.S. hospitals by 459 operators between March
2006 and January 2009.
Results The rates of death, stroke, and myocardial infarction and death and stroke (DS) at 30 days
were 3.5% and 3.3%, respectively, for the full CAPTURE 2 study cohort and 2.9% and 2.7%, re-
spectively, for the asymptomatic, nonoctogenarian subgroup. In this subgroup, two-thirds of sites
(118 of 180, 66%) had no DS events. Within the remaining sites, an inverse relationship between
event rates and hospital patient volume as well as between event rates and individual operator vol-
ume was observed. The DS rates trended lower for interventional cardiologists compared with other
specialties.
Conclusions Outcomes from the largest prospectively gathered, independently adjudicated, multi-
center CAS study indicate that CAS can be safely performed in a variety of hospital settings by phy-
sicians with various specialties. The most important determinant of perioperative CAS outcomes was
both site and operator CAS volume. A threshold of 72 cases was found to be necessary for consis-
tently achieving a DS rate below 3% in this later-phase single arm study; background era and non-
study operator experience will affect this determination. (Second Phase of “Carotid RX ACCULINK/RX
ACCUNET Post-Approval Trial to Uncover Unanticipated or Rare Events”; NCT00302237) (J Am Coll
Cardiol Intv 2011;4:235–46) © 2011 by the American College of Cardiology Foundation
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236In 2004, the U.S. Food and Drug Administration (FDA)
approved the first endovascular device system for use in the
U.S. for treatment of extracranial carotid artery disease in
patients at high risk for adverse events from carotid endar-
terectomy (CEA). Since then, carotid artery stenting (CAS)
has been performed with increasing numbers in a variety of
hospital settings. After the initial adoption phase in CAS,
there was a marked decrease in rates of adverse outcomes,
possibly related to improved patient selection and increased
operator experience (1). Because of this accumulating CAS
experience, a better understanding of the factors associated
with increased risk of adverse outcomes has been possible.
Over the past 5 years it has been demonstrated that
patient-related factors such as age (2–5), symptom status
(2,3), timing of symptoms before CAS (3–5), patient
comorbidities (4,6,7), concurrent medications (2), and
moking history (4) all might influence outcome. Carotid
rtery stenting outcomes are also impacted by physician-
elated factors, including training and experience, as well as
hospital volume (2). Most of
these factors are not yet well-
characterized, although the pro-
gression in our understanding of
risk predictors and the improve-
ment of outcomes for CAS
seems to mirror the experience
previously demonstrated for
CEA (8).
Given the incomplete under-
standing of the patient- and
physician-related features im-
pacting CAS outcomes, contin-
ued efforts to better quantify
these factors have led to further
examination of patient selection
nd operator experience (2,9). Prompted by the observation
hat in multicenter studies many hospital sites were able to
erform CAS with few or no adverse events—whereas
thers produced less favorable outcomes—there was a rec-
gnition of the need for a deeper understanding of what
pecific site and operator factors are associated with better
AS outcomes.
Accordingly, the aim of this study is to analyze the large
5,000 patients) CAPTURE 2 (Carotid ACCULINK/
CCUNET Post Approval Trial to Uncover Rare Events)
tudy for physician- or site-related variables associated with
ifferential outcomes, in an attempt to identify best prac-
ices.
ethods
Study design and current population. The CAPTURE 2
study is an ongoing, prospective, independently adjudicated,
Abbreviations
and Acronyms
AHA  American Heart
Association
CAS  carotid artery
stenting
CEA  carotid
endarterectomy
DS  death and stroke
DSMI  death, stroke, and
myocardial infarction
FDA  U.S. Food and Drug
Administration
IC  interventional
cardiologymulticenter clinical study designed to record safety out-comes of CAS associated with the use of the RX Acculink
Carotid Stent System and RX Accunet Embolic Protection
System (Abbott Vascular Incorporated, Santa Clara, Cali-
fornia) by physicians from a broad range of clinical practices
in high-risk patients. Device certification has been previ-
ously described (10). The CAPTURE 2 study is a post-
market clinical study, with a pre-specified protocol, in-
formed consent, institutional review board approval and
oversight, a pre-defined statistical and analytical plan con-
taining pre-defined primary and secondary end points,
pre-defined subgroup analyses, independent end point as-
sessment, and independent adjudication of neurological
events by an independent Clinical Event Committee, Har-
vard Clinical Research Institute, with site monitoring visits
and annual reporting to the FDA (see details to follow).
The CAPTURE 2 study was initiated in March 2006; the
data in the current analysis include a subgroup of evaluable
patients who had an attempted CAS procedure between
March 2006 and January 2009 and who were asymptomatic
and under the age of 80 years old. Asymptomatic patients
had no ipsilateral hemispheric stroke, transient ischemic
attack, or amaurosis fugax within 180 days before the
procedure. Age was computed at the day of procedure.
Patients were included if they completed their 30-day
follow-up visits or had any end point event (i.e., death,
stroke, or myocardial infarction within 30 days after the
procedure). All study patients were identified by the oper-
ators to have had characteristics that made them high-risk
for CEA and were asymptomatic with80% stenosis of the
common or internal carotid artery. Training requirements
for physicians in this study have been described previously
(10). Detailed descriptions of overall CAPTURE 2 study
objective and rationale and selection of interventionists and
patients were reported elsewhere (1).
Clinical sites, volume, and operators. The type and number
of staffed hospital beds for the CAPTURE 2 clinical sites
were manually annotated by reviewing the American Hos-
pital Directory database. The number of beds among
participating hospitals ranged from 30 to 2,236. Hospitals
were classified on the basis of self-description into 3 major
types: community, private, or academic (university). Facili-
ties were categorized by geography, with 4 major geographic
regions identified (Northeast, South, Midwest, and West),
with the classification system used by the U.S. Census Bureau.
Volume was defined as number of CAS procedures
performed in the CAPTURE 2 study at a single site or by
a single operator, as of the time of the analysis.
Operator specialty was obtained from the training records
and included: cardiology, vascular surgery, neurosurgery,
neuroradiology, and interventional radiology. Analysis was
presented on the first 2 (largest) groups, because the
remaining 3 groups had insufficient numbers for analysis.
Outcome assessment and end points. Detailed descriptions
of CAPTURE 2 study assessment and end points were
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237reported previously (1). Briefly, neurological evaluations were
performed on patients within 14 days before the stenting
procedure, within 24 h after the procedure, and at 30 days after
the procedure by an independent neurologist. Baseline demo-
graphic data, comorbidities, lesion characteristics, treatment
details, and information on adverse outcomes during the
procedure and at follow-up visits were collected with electronic
case report forms and entered into a centralized database.
During the 24-h post-procedure and 30-day follow-up assess-
ments, any occurrence of death, stroke, myocardial infarction,
new neurologic events, or device-related adverse events was
reported. Study subjects were evaluated for neurologic mani-
festations with the National Institutes of Health Stroke Scale
by a non-operator independent neurologist. A clinical events
adjudication committee, with pre-specified definitions, adjudi-
cated all suspected and confirmed strokes. Major stroke was
defined as any new neurologic deficit that resulted in an
increase in the National Institutes of Health Stroke Scale of
5 points from the pre-procedure score and was still present at
the 30-day follow-up visit. Strokes not meeting this definition
were categorized as minor.
Analyses. For the purposes of this analysis, only data from
onoctogenarian, asymptomatic subjects in the CAPTURE 2
tudy were considered for the following reasons:
. The selection of this patient population allows objective
assessment of the operator and clinical site or hospital
performance by excluding the 2 major known predictors
of adverse events, specifically symptomatic and octoge-
narian patients (2,3) that would otherwise confound the
analysis.
. The analysis uses American Heart Association (AHA)
guidelines for 30-day death/stroke outcomes for endar-
terectomy (having not been established for CAS) to
define site and operator outliers. Those AHA recom-
mendations were based on predicate data that largely
excluded the octogenarian population. Because there are
no accepted or established CEA thresholds for the
octogenarian population (lacking adequate data), none
could be used in this analysis.
. Because operators and sites have a different mix of
patient populations according to age and symptomatic
status, head-to-head comparisons would have been un-
balanced because there would be no way to establish a
“blended” threshold to identify outliers, therefore justi-
fying the subgroup analysis presented here.
. A separate analysis of nonoctogenarian symptomatic
patients was considered, because a threshold exists for
this group. However, although the CAPTURE 2 study
is the largest prospective, controlled carotid dataset ever
assembled, there are not enough symptomatic nonocto-
genarians to provide an adequately powered analysis.
Specifically, 553 patients spread over 459 operators and c180 sites would not adequately distinguish sites and
operators, due to the lack of precision in point estimates.
Baseline demographic, comorbidity, lesion, and procedural
nformation were summarized with descriptive summary sta-
istics. For variables involving proportions, counts, or percent-
ges, the Clopper-Pearson exact 2-sided 95% confidence
ntervals were presented. The statistics for continuous variables
ncluded sample size, mean, median, SD, minimum, and
aximum. For variables involving the differences between the
groups, asymptotic 95% confidence intervals were calculated.
inear regression modeling was conducted to analyze the
elationship between the outcome event rate and potentially
redictive variables from the clinical sites. Log transformation
as performed on the number of subjects per site and per
perator as well as on the 30-day death and stroke rates in the
inear regression analyses. All statistical analyses were per-
ormed with the SAS software (version 9.1.3, SAS Institute,
ary, North Carolina).
esults
The 30-day rates of death, stroke, and myocardial infarction
(DSMI) and death and stroke (DS) for the entire CAPTURE
2 cohort (n 5,297) were 3.5% and 3.3%, respectively. The
30-day DSMI and DS rates were 3.0% and 2.8%, respec-
tively, for asymptomatic subjects (n  4,337) and 6.0% and
5.7%, respectively, for the symptomatic subjects (n  721).
The 30-day DSMI and DS rates were 2.9% and 2.7%, re-
spectively, among asymptomatic nonoctogenarians (n  3,388)
and 4.5% and 4.2%, respectively, for symptomatic nonoctoge-
narians (n  553). Among octogenarians, symptomatic sub-
jects (n 168) had higher 30-day DSMI (10.7% vs. 3.3%) and
DS (10.7% vs. 3.2%) rates than asymptomatic subjects (n 
949). The 30-day major stroke rate for the entire cohort was
0.8% (44 of 5,297); for octogenarians and nonoctogenarians, it
was 1.2% (14 of 1,166) and 0.7% (30 of 4,131), respectively.
The subset of asymptomatic nonoctogenarians including
3,388 patients treated at 180 U.S. hospitals by 459 operators is
the focus of this analysis, as described in the Methods section.
Baseline demographic data for this CAPTURE 2 subset are
comparable (with the exception of age and symptom status) to
those of the overall population (Table 1).
Patient characteristics. Sites were divided into 2 groups on
he basis of 30-day DS rate or3%, corresponding to the
HA guidelines for acceptable 30-day DS rates for asymp-
omatic nonoctogenarians undergoing surgical revascular-
zation (CEA) (11,12). The demographic characteristics of
he 3% DS (group A, 127 sites and 2,072 patients) and
3% DS (group B, 53 sites and 1,316 patients) subsets were
omparable in terms of mean patient age (69.3 vs. 69.3
ears) and patient sex (62.3% vs. 60.3% male) distribution
Table 2). The medical histories of both cohorts were also
omparable, with the exception of incidence of congestive
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238Table 1. Baseline Demographic Data: All Evaluable Subjects Versus Asymptomatic and Nonoctogenarian
Subjects
All Evaluable Subjects
(n  5,297)
Asymptomatic, Nonoctogenarian
Subjects (n  3,388)
Age, yrs
Mean  SD (n) 72.3 9.2 (5,297) 69.3 7.4 (3,388)
Range (min–max) (34.1–100.3) (35.6–80.0)
(95% CI)* (72.1–72.6) (69.0–69.5)
Age 80 yrs 22.0% (1,166/5,297)
(95% CI)† (20.9%–23.2%)
Sex
Male 61.7% (3,266/5,297) 61.5% (2,083/3,388)
(95% CI)† (60.3%–63.0%) (59.8%–63.1%)
Medical history
Symptomatic (ipsilateral stroke, TIA, amaurosis fugax
180 days)
14.3% (721/5,058)
(95% CI)† (13.3%–15.2%)
Diabetes 36.5% (1,925/5,279) 38.7% (1,305/3,375)
(95% CI)† (35.2%–37.8%) (37.0%–40.3%)
Hypertension 89.2% (4,701/5,271) 89.1% (3,002/3,371)
(95% CI)† (88.3%–90.0%) (88.0%–90.1%)
Hypercholesterolemia 88.7% (4,609/5,198) 90.0% (3,008/3,343)
(95% CI)† (87.8%–89.5%) (88.9%–91.0%)
Current tobacco user 23.1% (1,177/5,085) 26.3% (862/3,279)
(95% CI)† (22.0%–24.3%) (24.8%–27.8%)
CHF 18.3% (958/5,240) 18.4% (616/3,352)
(95% CI)† (17.2%–19.4%) (17.1%–19.7%)
Prior MI 26.1% (1,306/5,008) 27.5% (888/3,232)
(95% CI)† (24.9%–27.3%) (25.9%–29.0%)
MI within 30 days 0.9% (45/5,008) 1.1% (34/3,232)
(95% CI)† (0.7%–1.2%) (0.7%–1.5%)
Needs CABG within 30 days 4.8% (239/4,995) 5.3% (170/3,226)
(95% CI)† (4.2%–5.4%) (4.5%–6.1%)
Arrhythmia 21.0% (1,098/5,221) 19.0% (635/3,349)
(95% CI)† (19.9%–22.2%) (17.6%–20.3%)
Coronary artery disease 73.2% (3,768/5,151) 74.4% (2,461/3,307)
(95% CI)† (71.9%–74.4%) (72.9%–75.9%)
Unstable angina 9.4% (485/5,150) 10.1% (333/3,307)
(95% CI)† (8.6%–10.2%) (9.1%–11.1%)
COPD 22.3% (1,160/5,204) 24.7% (824/3,336)
(95% CI)† (21.2%–23.4%) (23.2%–26.2%)
Renal insufﬁciency‡ 18.7% (979/5,244) 17.9% (601/3,360)
(95% CI)† (17.6%–19.8%) (16.6%–19.2%)
Renal failure 3.3% (173/5,244) 3.4% (115/3,360)
(95% CI)† (2.8%–3.8%) (2.8%–4.1%)
Unfavorable anatomic conditions 21.8% (1,153/5,291) 22.0% (746/3,386)
(95% CI)† (20.7%–22.9%) (20.6%–23.5%)
Contralateral occlusion of ICA 16.9% (860/5,081) 18.1% (589/3,259)
(95% CI)† (15.9%–18.0%) (16.8%–19.4%)
Peripheral vascular disease 45.6% (2,299/5,037) 47.7% (1,550/3,248)
(95% CI)† (44.3%–47.0%) (46.0%–49.5%)
Prior CEA 16.8% (888/5,293) 18.3% (618/3,386)
(95% CI)† (15.8%–17.8%) (17.0%–19.6%)
Other signiﬁcant disease 41.6% (2,202/5,297) 41.6% (1,410/3,388)
(95% CI)† (40.2%–42.9%) (40.0%–43.3%)
*By normal approximation. †Clopper-Pearson exact confidence interval (CI). ‡A subgroup of subjects with renal insufficiency were reported as
having renal failure.
CABG coronary artery bypass grafting; CEA carotid endarterectomy; CHF congestive heart failure; COPD chronic obstructive pulmonarydisease; ICA internal carotid artery; MImyocardial infarction; TIA transient ischemic attack.
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239heart failure (CHF), which was significantly more frequent
in group B (21.0%) than in group A (16.7%).
The site-reported vessel characteristics for the subject
population are presented in Table 3. There was no evidence
of any statistically significant difference between the 2
groups in terms of lesion location (left or right), percentage
stenosis, plaque echogenocity, thrombus, or lesion length.
However, higher DS rates (group B) were significantly asso-
ciated with greater target lesion calcifications, more complex
aortic arch anatomy, and atherosclerotic arch involvement.
Site characteristics. The 30-day periprocedural DS rate for
ach clinical site was plotted along with its respective patient
Table 2. Baseline Demographic Data for Nonoctogen
Low and High Death/Stroke Rate Subgroups
Low-Rate (<3%) Si
(n  2,072)
Age
Mean  SD (n) 69.3 7.4 (2,072)
Range (min–max) (35.6–80.0)
(95% CI)* (68.9–69.6)
Sex
Male 62.3% (1,290/2,072
(95% CI)† (60.1%–64.4%)
Medical history
Diabetes 38.0% (786/2,066)
(95% CI)† (35.9%–40.2%)
Hypertension 89.3% (1,836/2,057
(95% CI)† (87.8%–90.6%)
Hypercholesterolemia 90.8% (1,857/2,046
(95% CI)† (89.4%–92.0%)
Current tobacco user 27.3% (548/2,009)
(95% CI)† (25.3%–29.3%)
CHF 16.7% (343/2,049)
(95% CI)† (15.1%–18.4%)
Prior MI 26.4% (522/1,977)
(95% CI)† (24.5%–28.4%)
Arrhythmia 18.6% (380/2,045)
(95% CI)† (16.9%–20.3%)
Coronary artery disease 75.0% (1,522/2,029
(95% CI)† (73.1%–76.9%)
COPD 24.9% (509/2,046)
(95% CI)† (23.0%–26.8%)
Renal insufﬁciency 18.2% (374/2,050)
(95% CI)† (16.6%–20.0%)
Unfavorable anatomic conditions 22.8% (473/2,072)
(95% CI)† (21.0%–24.7%)
Contralateral occlusion of ICA 17.6% (354/2,009)
(95% CI)† (16.0%–19.4%)
Peripheral vascular disease 47.2% (943/2,000)
(95% CI)† (44.9%–49.4%)
Prior CEA 18.2% (376/2,071)
(95% CI)† (16.5%–19.9%)
*By normal approximation. †Clopper-Pearson exact CI. ‡StatisticallyAbbreviations as in Table 1.olume (Fig. 1A). Event rates were calculated as percentages
y dividing the number of DS events (left y axis) by the total
umber of patients (right y axis) at a given site. Two-thirds
f sites (118 of 180, 66%) had no DS events and therefore
ad an event rate of 0%. One site is an outlier with 1 patient
nd 1 DS event (thus 100% DS rate) and was excluded from
urther analysis. Exclusion of this site does not change the
esults and conclusions of the analysis but improves the
raphical representation of data. The remaining one-third,
1 sites, had at least 1 DS event, with the majority (52 of
1%, 85%) of these sites having DS rates exceeding 3%.
ithin the 61 sites with DS events, an inverse relationship
Asymptomatic Subjects by
High-Rate (>3%) Sites
(n  1,316) Difference (95% CI)*
69.3 7.4 (1,316) 0.07 (0.58 to 0.44)
(43.8–80.0)
(68.9–69.7)
60.3% (793/1,316) 2.00% (1.37% to 5.37%)
(57.6%–62.9%)
39.6% (519/1,309) 1.60% (4.98% to 1.77%)
(37.0%–42.4%)
88.7% (1,166/1,314) 0.52% (1.65% to 2.69%)
(86.9%–90.4%)
88.7% (1,151/1,297) 2.02% (0.11% to 4.15%)
(86.9%–90.4%)
24.7% (314/1,270) 2.55% (0.52% to 5.62%)
(22.4%–27.2%)
21.0% (273/1,303) 4.21%‡ (6.95% to1.47%)
(18.8%–23.3%)
29.2% (366/1,255) 2.76% (5.94% to 0.42%)
(26.7%–31.8%)
19.6% (255/1,304) 0.97% (3.71% to 1.76%)
(17.4%–21.8%)
73.5% (939/1,278) 1.54% (1.53% to 4.61%)
(71.0%–75.9%)
24.4% (315/1,290) 0.46% (2.54% to 3.46%)
(22.1%–26.9%)
17.3% (227/1,310) 0.92% (1.73% to 3.56%)
(15.3%–19.5%)
20.8% (273/1,314) 2.05% (0.79% to 4.89%)
(18.6%–23.1%)
18.8% (235/1,250) 1.18% (3.91% to 1.55%)
(16.7%–21.1%)
48.6% (607/1,248) 1.49% (5.02% to 2.04%)
(45.8%–51.5%)
18.4% (242/1,315) 0.25% (2.92% to 2.43%)
(16.3%–20.6%)
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240Table 3. Vessel Characteristics for Nonoctogenarian Asymptomatic Subjects by Low and High Death/Stroke Rate Subgroups
Low-Rate (<3%) Sites
(n  2,072 Patients, 2,102 Lesions)
High-Rate (>3%) Sites
(n  1,316 Patients, 1,326 Lesions) Difference (95% CI)*
Lesion location
Left internal carotid 45.1% (949/2,102) 45.2% (599/1,326) 0.03% (3.45% to 3.39%)
(95% CI)† (43.0%–47.3%) (42.5%–47.9%)
Right internal carotid 44.2% (929/2,102) 44.2% (586/1,326) 0.00% (3.41% to 3.42%)
(95% CI)† (42.1%–46.3%) (41.5%–46.9%)
Left common carotid 4.7% (99/2,102) 4.4% (59/1,326) 0.26% (1.17% to 1.69%)
(95% CI)† (3.8%–5.7%) (3.4%–5.7%)
Right common carotid 3.7% (78/2,102) 3.2% (43/1,326) 0.47% (0.78% to 1.72%)
(95% CI)† (2.9%–4.6%) (2.4%–4.3%)
Left internal carotid/left common carotid 1.4% (29/2,102) 1.4% (19/1,326) 0.05% (0.86% to 0.76%)
(95% CI)† (0.9%–2.0%) (0.9%–2.2%)
Right internal carotid/right common carotid 0.9% (18/2,102) 1.5% (20/1,326) 0.65% (1.42% to 0.11%)
(95% CI)† (0.5%–1.4%) (0.9%–2.3%)
Target lesion stenosis (%)
Mean  SD (n) 85.9 7.2 (2,102) 86.1 7.7 (1,325) 0.25 (0.76 to 0.26)
Range (min–max) (49.0–99.0) (50.0–99.0)
(95% CI)* (85.5–86.2) (85.7–86.5)
Target lesion length (mm)
Mean  SD (n) 18.5 8.5 (2,095) 18.1 9.4 (1,324) 0.39 (0.22 to 1.00)
Range (min–max) (2.0–100.0) (2.0–80.0)
(95% CI)* (18.1–18.9) (17.6–18.6)
Target site calciﬁcation
None 25.9% (544/2,097) 21.7% (288/1,325) 4.21%‡ (1.30% to 7.11%)
(95% CI)† (24.1%–27.9%) (19.5%–24.1%)
Mild 51.5% (1,080/2,097) 57.8% (766/1,325) 6.31%‡ (9.72% to2.90%)
(95% CI)† (49.3%–53.7%) (55.1%–60.5%)
Heavy 22.6% (473/2,097) 20.5% (271/1,325) 2.10% (0.71% to 4.92%)
(95% CI)† (20.8%–24.4%) (18.3%–22.7%)
Thrombus present at target site 3.0% (62/2,101) 2.5% (33/1,326) 0.46% (0.65% to 1.57%)
(95% CI)† (2.3%–3.8%) (1.7%–3.5%)
Aortic arch type
I 49.3% (1,021/2,070) 44.9% (593/1,320) 4.40%‡ (0.96% to 7.84%)
(95% CI)† (47.1%–51.5%) (42.2%–47.7%)
II 40.7% (842/2,070) 44.2% (583/1,320) 3.49%‡ (6.90% to0.08%)
(95% CI)† (38.6%–42.8%) (41.5%–46.9%)
III 10.0% (207/2,070) 10.9% (144/1,320) 0.91% (3.03% to 1.21%)
(95% CI)† (8.7%–11.4%) (9.3%–12.7%)
Target lesion echogenicity
Completely soft 24.2% (489/2,022) 22.2% (285/1,283) 1.97% (0.97% to 4.91%)
(95% CI)† (22.3%–26.1%) (20.0%–24.6%)
Completely calciﬁed 7.5% (152/2,022) 8.6% (110/1,283) 1.06% (2.97% to 0.86%)
(95% CI)† (6.4%–8.8%) (7.1%–10.2%)
Mixed 68.3% (1,381/2,022) 69.2% (888/1,283) 0.91% (4.15% to 2.33%)
(95% CI)† (66.2%–70.3%) (66.6%–71.7%)
Aortic arch characteristic
Diseased 44.9% (934/2,079) 51.1% (668/1,307) 6.18%‡ (9.64% to2.73%)
(95% CI)† (42.8%–47.1%) (48.4%–53.9%)
Nondiseased 55.1% (1,145/2,079) 48.9% (639/1,307) 6.18%‡ (2.73% to 9.64%)
(95% CI)† (52.9%–57.2%) (46.1%–51.6%)*By normal approximation. †Clopper-Pearson exact confidence interval (CI). ‡Statistically significant.
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241between event rates and patient volume was noted graphi-
cally (Fig. 1A) and represented quantitatively by a linear
regression with log transformation of both variables to
better reflect the nature of the observation. The result is
given by the equation log(y)  4.43  0.74*log(x), where y
epresents DS rates and x represents volume in number of
atients/site, with p value for slope 0.0001, and r2  0.53
(Fig. 1B).
Of the 118 sites without any DS events, patient volumes
ranged widely. Low-volume sites (i.e., with less than 10
cases) have too small a sample size to accurately predict DS
rates. In addition, adding a single event to a low-volume site
would result in a high DS rate because of the smaller
denominator, therefore confirming the inverse relationship
observed with sites with DS events. In the same manner, a
high-volume non-event site would have a low DS rate if
their next case had an event, because of the larger denom-
inator, therefore confirming again the inverse relationship
observed. As a sensitivity analysis and to verify the validity
Figure 1. Patient DS Rate by Site and Patients/Site and Linear
Regression of DS
(A) Death and stroke (DS) rate of nonoctogenarian asymptomatic patients
by site and number of patients/site (dotted horizontal line indicates
American Heart Association guideline of 3% event rate for asymptomatic
patients). (B) Linear regression of DS on number of patients/site.of the methodology, 1 DS event was added to all sites withno events, then the plot was assessed, and a log-log regression
analysis performed. A relationship similar to that seen in the
sites with DS events was observed, and the regression showed
lower p value and higher r2, indirectly confirming and provid-
ng robustness to the original interpretation.
There was no evidence that hospital type or hospital
eographic location had significant influence on outcomes
t the p  0.05 level (Table 4). Baseline demographic and
esion vessel characteristics of the patients were comparable
cross types of hospitals and hospital geographic regions.
he DS rates were plotted against the number of staffed
eds/hospital to evaluate whether outcomes were influenced
y hospital size. No apparent relationship was observed (Fig.
A). The lack of association was confirmed by a linear
egression analysis, with p value for slope 0.4131, and r2 0.01
Fig. 2B).
Operator characteristics. To assess whether the inverse re-
lationship between volume and DS rates was related not just
to site volume but also to the individual operator volume,
DS rates were plotted for each operator. Four of 5 operators
(348 of 425, 82%) had no DS events and therefore had an
event rate of 0%. The remaining 20%, 77 operators, had at
least 1 DS event; 71 (92%) of these operators had DS rates
exceeding 3% of their patient volume. An inverse relation-
ship between event rates and operator volume was again
observed (Fig. 3A). After log transformation of both vari-
ables, a simple linear regression was done to quantitatively
assess the relationship. The result is given by the equation
log(y)  4.71  0.85*log(x), where y represents DS rates
and x represents volume in number of patients/operator,
with p value for slope 0.0001, and r2  0.81 (Fig. 3B).
To further investigate whether the results were similar or
discordant across the specialties of the operators, linear
regression was performed for each of the 5 specialties. The
results were consistent across all specialties, confirming that
individual operator volume was a determinant of outcome,
independent of the specialty of the operator; analyses were
presented for the 2 largest groups (Figs. 4A to 4D).
A summary of periprocedural outcomes by physician
specialty is presented in Table 5. The baseline demographic
data, comorbidities, and site-reported carotid lesion charac-
teristics of the patient population treated by each physician
specialty were comparable, with the exception that vascular
surgery patients had less reported target lesion calcification
and aortic arch disease, fewer type III arches, more prior
CEA, and more contralateral occlusion of the internal
carotid artery. Interventional cardiology (IC) patients had
more coronary artery disease, unstable angina, and periph-
eral artery disease than any other specialty. Patients treated
by IC, which represented the largest proportion, tended to
have lower DS rates than the other specialties, although
these differences were not statistically significant at the 0.05
level. Of interest, among the only 2 specialties with suffi-
cient patient volumes to allow for comparison, the ratio of
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242minor/major strokes in patients treated by IC was approx-
imately 2.5, compared with a ratio of approximately 1.25 for
patients treated by vascular surgery, suggesting a potential
difference in the mix of stroke severity between these 2
roups. No differences were observed between specialties in
ocation of stroke (ipsilateral vs. non-ipsilateral) for either
ajor or minor strokes.
iscussion
The CAPTURE 2 study represents the highest level of
scientific inquiry for a post-market study and should be
differentiated from a registry, which is characterized by
self-reported events and no adjudication. This analysis of
the CAPTURE 2 data was initiated by the observation
that there were outcome disparities among participating
sites and that, by identifying predictors of those differ-
ences, clinical results might further improve. The analysis
was restricted to a large subgroup of patients to eliminate
the influence of the 2 key predictors of outcome, symp-
tomatic status and age (80 years and over). Site and
individual operator case volume correlated most strongly
with outcome, confirming other previous observations
(2,13–16). Among the multiple patient factors assessed,
congestive heart failure and certain anatomic features
were more frequent in sites with DS higher than AHA
guideline standards. Although specialty training of the
operators did not influence the frequency of outcome
events, the severity of stroke seemed to vary by operator
specialty.
Improvement of CAS peri-procedural outcomes. The
APTURE 2 study represents a valuable source of pro-
pectively gathered, adjudicated CAS outcome data. It
urrently includes 5,279 evaluable patients treated at 184
Table 4. Death and Stroke Events Within 30 Days by Hospital Type and Re
Events
Community Hospital
(n  433)
(M  24)
Private Hospital
(n  1,101)
(M  67)
Teachin
(n 
(M
Death 0.0% (0/433) 0.8% (9/1,101) 1.0% (
(95% CI)* (0.0%–0.8%) (0.4%–1.5%) (0.6%
All stroke 2.5% (11/433) 1.7% (19/1,101) 2.2% (
(95% CI)* (1.3%–4.5%) (1.0%–2.7%) (1.6%
Major stroke 0.9% (4/433) 0.5% (6/1,101) 0.6% (
(95% CI)* (0.3%–2.3%) (0.2%–1.2%) (0.3%
Minor stroke 1.8% (8/433) 1.2% (13/1,101) 1.6% (
(95% CI)* (0.8%–3.6%) (0.6%–2.0%) (1.0%
Death–stroke† 2.5% (11/433) 2.4% (26/1,101) 2.9% (
(95% CI)* (1.3%–4.5%) (1.5%–3.4%) (2.1%
Death–major stroke† 0.9% (4/433) 1.2% (13/1,101) 1.3% (
(95% CI)* (0.3%–2.3%) (0.6%–2.0%) (0.8%
N 3,388. *Clopper-Pearson exact confidence interval (CI). †Only includes each subject’s first occu
n number of patients; M number of hospitals.ospitals and by 459 physicians from a variety of specialties it community, private, and teaching hospitals. The 30-day
S rate for the entire cohort of 5,297 patients was 3.5%, a
ignificant improvement over that demonstrated in earlier
AS clinical trials with many fewer investigators and sites,
here overall rates were 7% to 8% (SAPPHIRE [Stenting
nd Angioplasty with Protection in Patients at HIgh Risk
or Endarterectomy], ARCHeR [ACCULINK for Revas-
ularization of Carotids in High-Risk patients]) (17). For
atients 80 years of age (nonoctogenarians), the DS rate
or asymptomatic and symptomatic patients was 2.7% and
.7%, respectively; both rates are well within the AHA
uidelines defining acceptable risk of DS with carotid
ndarterectomy in asymptomatic (3%) and symptomatic
6%) patients. Importantly and to put the results from the
APTURE 2 study in proper context, these AHA guidelines
ere developed on the basis of evidence from carotid endar-
erectomy in the population of patients for whom surgery was
tandard risk; because the CAPTURE 2 study enrolled only
atients considered higher-risk for endarterectomy, the attain-
ent of DS rates within the AHA guideline is notable. It
hould also be noted that improvements relative to earlier trials
10) are also observed in both the overall and subset (octoge-
arian, symptomatic, and so forth) populations.
Understanding factors that place patients at risk for
erioperative complications facilitates continued improve-
ent in CAS outcomes. Since the advent of CAS, efforts
ave been made to understand which patient and physician
actors are associated with adverse outcomes in the peripro-
edural (30 days) period. Numerous studies (2–7,18–22)
nalyzing risk factors for CAS have identified patient-
elated factors, such as age and symptom status. Less is
nown about physician- and site-related variables that
mpact outcome. The current study illuminates the potential
for Asymptomatic Subjects <80 Years of Age
pital
)
Midwest
(n  1,017)
(M  53)
Northeast
(n  675)
(M  29)
South
(n  1,338)
(M  71)
West
(n  358)
(M  27)
54) 0.8% (8/1,017) 0.6% (4/675) 1.1% (15/1,338) 0.0% (0/358)
) (0.3%–1.5%) (0.2%–1.5%) (0.6%–1.8%) (0.0%–1.0%)
54) 2.5% (25/1,017) 2.1% (14/675) 1.9% (26/1,338) 1.7% (6/358)
) (1.6%–3.6%) (1.1%–3.5%) (1.3%–2.8%) (0.6%–3.6%)
54) 0.4% (4/1,017) 0.6% (4/675) 0.8% (11/1,338) 0.8% (3/358)
) (0.1%–1.0%) (0.2%–1.5%) (0.4%–1.5%) (0.2%–2.4%)
54) 2.1% (21/1,017) 1.5% (10/675) 1.1% (15/1,338) 1.1% (4/358)
) (1.3%–3.1%) (0.7%–2.7%) (0.6%–1.8%) (0.3%–2.8%)
54) 3.2% (33/1,017) 2.4% (16/675) 2.6% (35/1,338) 1.7% (6/358)
) (2.2%–4.5%) (1.4%–3.8%) (1.8%–3.6%) (0.6%–3.6%)
54) 1.2% (12/1,017) 0.9% (6/675) 1.5% (20/1,338) 0.8% (3/358)
) (0.6%–2.1%) (0.3%–1.9%) (0.9%–2.3%) (0.2%–2.4%)
of the most serious event.gion
g Hos
1,854
 89)
18/1,8
–1.5%
41/1,8
–3.0%
12/1,8
–1.1%
29/1,8
–2.2%
53/1,8
–3.7%
24/1,8
–1.9%
rrencempact of these other factors. Interventionists with different
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243specialty-training backgrounds and experience levels are
performing CAS. Training, competency, and credentialing
standards will continue to be developed and refined for CAS
operators—as was the case with CEA (23,24)—and should
be predicated on an understanding of the physician factors
associated with successful CAS outcomes.
Inﬂuence of patient volume on periprocedural outcome. The
availability of this large dataset of independently adjudicated
CAS outcomes provides a unique opportunity to investigate
physician-associated factors influencing outcomes, to help
identify “best practice” guidelines for practitioners. It is
noteworthy that most sites (118 of 180, 66%) did not report
any events in the 30-day period after CAS. The remaining
61 sites reporting events become an important source of
information regarding factors that influence outcome. A
striking inverse relationship between DS rate and patient
volume was identified at these sites: the more patients
treated, the lower the event rate (r2  0.53) (Fig. 1). This was
ven more pronounced when outcomes and patient numbers
Figure 2. Patient DS Rate and Number of Staffed Beds/Hospital and Lin-
ear Regression of DS Rate on Number of Staffed Beds/Hospital
(A) Death and stroke (DS) rate of nonoctogenarian asymptomatic patients and
number of staffed beds/hospital (dotted horizontal line indicates American
Heart Association guideline of 3% event rate for asymptomatic patients). (B)
Linear regression of DS rate on number of staffed beds/hospital.ere stratified by individual physician volume (r2  0.81)Fig. 2). Notably, the relationship between higher operator and
ite patient volume and favorable outcomes has also been
eported for CEA (13,15).
The regression model derived from the CAPTURE 2 study
an be used to estimate the minimum number of carotid artery
tenting procedures to achieve a DS rate below 3%. Replacing
he value of 3% in the equation, log(rate)  4.71 to 0.845
log(case), yields a minimum case number of 72. This value is
higher than what has been suggested in the past or what has
served as the threshold for enrolling patients in randomized
trials like the CREST (Carotid Revascularization Endarterec-
tomy vs. Stenting Trial) or ACT I (Carotid Stenting vs.
Surgery of Severe Carotid Artery Disease and Stroke Preven-
tion in Asymptomatic Patients) trials.
Center volume was also found to be a significant predictor of
peri-interventional death and stroke in a recent analysis of the
Pro-CAS (Prospective Registry of Carotid Artery Stenting)
data (2). Although individual operator experience was not
captured in the Pro-CAS study, estimation of the appropriate
individual physician learning curves (15 interventions) was
Figure 3. Patient DS Rate and Number of Patients/Physician and
Linear Regression of DS Rate on Number of Patients/Physician
(A) Death and stroke (DS) rate of nonoctogenarian asymptomatic patients and
number of patients/physician (dotted horizontal line indicates American
Heart Association guideline of 3% event rate for asymptomatic patients). (B)
Linear regression of DS rate on number of patients/physician.
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244based on a mean number of cases/operator/site. In the current
analysis, data regarding individual operator volume were avail-
able, allowing a more precise examination of the relationship
between physician caseload and outcome. The association of
higher adverse outcome rates with low patient volume under-
scores the importance of experience. Although various early
credentialing documents have recommended minimum num-
bers of proctored procedures, (25) the number of CAS inter-
ventions (both observed and proctored) required for an oper-
ator to become competent has not yet been established in the
published reports on the basis of outcome data.
Impact of physician training. It should be noted that the
CAPTURE 2 study was neither designed nor powered to
show outcome differences for physician specialties. There
seemed to be trends in volume according to operator
specialty: the mean number of patients treated per
surgeon was 6.5 (725 patients treated by 112 physicians)
and per cardiologists was 9.1 (2,312 patients treated by 255
physicians). The inverse relationship of patient volume and
periprocedural outcomes was independent of physician spe-
cialty, suggesting that highly experienced operators from any of
the specialties achieve better outcomes. Although we found no
Figure 4. Patient DS by Specialty
(A) Death and stroke (DS) rate by number of patients/physician for interventio
guideline of 3% event rate for asymptomatic patients). (B) Linear regression o
number of patients for vascular surgeons (dotted horizontal line indicates Am
(D) Linear regression of DS rate by number of patients for vascular surgeons.evidence of significant differences in outcome rates by specialty, tthere seem to be disparities in ratios of minor to major strokes
for the different specialties.
Reﬂections on current processes and future trials. This anal-
ysis confirms the value of FDA-mandated, post-market ap-
proval surveillance studies in data-collection and possible pro-
cess improvements. This is especially relevant in a technically
demanding procedure such as CAS. Furthermore, the finding
of volume/experience as predictor of outcome is important not
only for the analysis of prior studies and their results but also to
establish the experience and training requirements for future
trials as a way to eliminate unqualified operators as potential
confounders of outcomes.
Study limitations and strengths. The analyses presented in
his report were not pre-specified at the start of the study
r in the protocol; however, they were pre-defined at the
oncept stage of the report and are based on a large
ubgroup of asymptomatic nonoctogenarian patients.
herefore, we should caution the reader about making
trong inferential statements, because most of the anal-
ses should be interpreted as exploratory. However, given
he large cohort explored, these analyses have value and
dd to the weight of evidence that experience matters in
rdiologists (dotted horizontal line indicates American Heart Association
te by number of patients for interventional cardiologists. (C) The DS rate by
n Heart Association guideline of 3% event rate for asymptomatic patients).nal ca
f DS ra
ericaechnical procedures.
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245Another limitation of the current analysis is the lack of
information about the true CAS volume of both operators
and sites. This analysis only includes CAPTURE 2 patients
and ignores the overall site or operator volume performed
outside of the study. For much of the course of enrollment
in the CAPTURE 2 study, availability of CAS outside of
the study at these sites and for these operators was limited.
Despite the absence of data regarding overall CAS volumes,
the strength of the relationships associating CAS volume to
outcome in the CAPTURE 2 study alone is evidenced by
high values of the coefficient of determination r2.
Lastly, although data on the angiographic and lesion
characteristics were analyzed and seemed to yield outcome
predictors (e.g., aortic arch type), the lack of an angio-
graphic or ultrasound core laboratory limits the strength of
these findings.
Conclusions
Outcomes from the largest prospectively gathered, indepen-
dently adjudicated, multicenter CAS study indicate that
CAS can be safely performed in a variety of hospital settings
by physicians with various specialties. The most important
determinant of perioperative CAS outcomes was both site
and operator CAS volume. A threshold of 72 cases was
found to be necessary for consistently achieving a DS rate
Table 5. Death and Stroke Events Within 30 Days by Physician Specialty f
Interventional
Cardiologist
(n  255 inv)
(N  2,312 pts)
Interventio
Neuroradiol
(n  19 i
(N  132
Hierarchical events*
All death, stroke, and MI 2.7% (63/2,312) 3.0% (4/13
(95% CI)† (2.1%–3.5%) (0.8%–7.6
All stroke, death 2.5% (58/2,312) 3.0% (4/13
(95% CI)† (1.9%–3.2%) (0.8%–7.6
Major stroke, death 1.1% (26/2,312) 1.5% (2/13
(95% CI)† (0.7%–1.6%) (0.2%–5.4
Nonhierarchical events*
Death 0.6% (15/2,312) 1.5% (2/13
(95% CI)† (0.4%–1.1%) (0.2%–5.4
All stroke 1.9% (45/2,312) 1.5% (2/13
(95% CI)† (1.4%–2.6%) (0.2%–5.4
Major stroke 0.6% (13/2,312) 0.0% (0/13
(95% CI)† (0.3%–1.0%) (0.0%–2.8
Minor stroke 1.4% (33/2,312) 1.5% (2/13
(95% CI)† (1.0%–2.0%) (0.2%–5.4
MI 0.4% (9/2,312) 0.0% (0/13
(95% CI)† (0.2%–0.7%) (0.0%–2.8
*Only includes the first occurrence of the most serious event for each subject. †Clopper-Pearson e
MImyocardial infarction; N number of patients; n number of investigators (inv).below 3%.Acknowledgments
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